Payment overview · 2025
General Payments
$32.24
2 reported records · 2 companies
Healthcare provider profile · identity verified
Gregory S. Harrah, MD
Allopathic & Osteopathic Physicians|Family Medicine · HURRICANE, WV · NPI 1528022795
Verified facts
What the public records show
CMS Open Payments records show Gregory S. Harrah, MD received $32.24 in general payments during 2025 across 2 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 50.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.40 | 50.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.84 | 49.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $32.24 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 335 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 296 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 244 | 34 |
| Losartan Potassium | Losartan Potassium | 231 | 63 |
| Gabapentin | Gabapentin | 223 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 62 |
| Lisinopril | Lisinopril | 202 | 53 |
| Lorazepam | Lorazepam | 199 | 32 |
| Metformin Hcl | Metformin Hcl | 182 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 50 |
| Tramadol Hcl | Tramadol Hcl | 169 | 28 |
| Potassium Chloride | Potassium Chloride | 164 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 23 |
| Famotidine | Famotidine | 133 | 35 |
| Alprazolam | Alprazolam | 131 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 35 |
| Glimepiride | Glimepiride | 122 | 30 |
| Clonazepam | Clonazepam | 113 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 31 |
| Ozempic | Semaglutide | 107 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 22 |
| Pregabalin | Pregabalin | 104 | 22 |
| Sertraline Hcl | Sertraline Hcl | 99 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 25 |
| Montelukast Sodium | Montelukast Sodium | 92 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 22 |
| Meloxicam | Meloxicam | 90 | 21 |
| Azithromycin | Azithromycin | 87 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 17 |
| Simvastatin | Simvastatin | 82 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 18 |
| Torsemide | Torsemide | 74 | 21 |
| Amoxicillin | Amoxicillin | 69 | 45 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | suppressed |
| Prednisone | Prednisone | 69 | 49 |
| Eliquis | Apixaban | 66 | 16 |
| Furosemide | Furosemide | 64 | 27 |
| Atenolol | Atenolol | 62 | 15 |
| Ibuprofen | Ibuprofen | 61 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 20 |
| Mounjaro | Tirzepatide | 59 | 11 |
| Memantine Hcl | Memantine Hcl | 57 | suppressed |
| Carvedilol | Carvedilol | 55 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 11 |
| Allopurinol | Allopurinol | 52 | 14 |
| Trazodone Hcl | Trazodone Hcl | 51 | 12 |
| Buspirone Hcl | Buspirone Hcl | 50 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 36 |
| Ezetimibe | Ezetimibe | 46 | 12 |
| Januvia | Sitagliptin Phosphate | 46 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | 13 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 15 |
| Cephalexin | Cephalexin | 42 | 28 |
| Diclofenac Potassium | Diclofenac Potassium | 42 | 20 |
| Glipizide | Glipizide | 41 | 12 |
| Azelastine Hcl | Azelastine Hcl | 40 | 21 |
| Methylprednisolone | Methylprednisolone | 40 | 34 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 15 |
| Diclofenac Sodium Er | Diclofenac Sodium | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Etodolac | Etodolac | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Estradiol | Estradiol | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dapsone | Dapsone | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $32.24 · 2 records | E.R. Squibb & Sons, L.L.C. | ELIQUIS, Veozah | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error